Management of mycoses in daily practice

L. Drago, G. Micali, M. Papini, B.M. Piraccini, S. Veraldi

Research output: Contribution to journalArticle

Abstract

The guideline recommendations, albeit founded on thorough reviews of clinically relevant literature data, are often not immediately adaptable to everyday life. Considering the marked heterogeneity of superficial mycoses, each of them requires specific management in a real life context; in all cases diagnostic confirmation is required with microscopic and culture examination. In tinea capitis oral therapy is necessary (minimum six weeks) and should be continued until clinical and, above all, mycological healing. In cases of tinea corporis, cruris or pedis, it may be necessary to associate oral therapy to topical treatment. The main oral antifungals are fluconazole, itraconazole and terbinafine. Fluconazole has favorable pharmacokinetic and pharmacodynamic characteristics, and is effective in most superficial mycoses, for example in cases of diffuse or recurrent pityriasis versicolor in which oral therapy with an azole derivative is useful. Topical treatment, lasting 6-12 months, is indicated in onychomycosis that is confined to one nail. In frequent cases of onychomycosis involving multiple nails or recurrence, oral therapy is necessary. Pharmacological history is important, given the possible interactions of some systemic drugs. In chronic or recurrent relapsing vulvovaginitis, first-choice therapy is oral fluconazole with a therapeutic regimen that respects the mycotic biorhythm (200 mg on days 1, 4, 11, 26, and subsequently 200 mg/week for 3 months).
Original languageEnglish
Pages (from-to)642-650
Number of pages9
JournalGiornale Italiano di Dermatologia e Venereologia
Volume152
Issue number6
DOIs
Publication statusPublished - 2017

Fingerprint

Mycoses
Fluconazole
Onychomycosis
terbinafine
Nails
Therapeutics
Vulvovaginitis
Tinea Versicolor
Tinea Capitis
Azoles
Tinea
Itraconazole
Periodicity
Pharmacokinetics
History
Pharmacology
Guidelines
Recurrence
Pharmaceutical Preparations

Keywords

  • allylamine
  • amorolfine
  • antifungal agent
  • ciclopirox
  • fluconazole
  • griseofulvin
  • itraconazole
  • miconazole
  • nystatin
  • terbinafine, candidiasis
  • chemical binding
  • dermatophytosis
  • drug bioavailability
  • drug elimination
  • drug half life
  • fungicidal activity
  • human
  • maximum plasma concentration
  • mycosis
  • nonhuman
  • onychomycosis
  • Review
  • tinea capitis
  • tinea corporis
  • tinea cruris
  • tinea pedis
  • tinea versicolor
  • vulvovaginitis
  • yeast

Cite this

Management of mycoses in daily practice. / Drago, L.; Micali, G.; Papini, M.; Piraccini, B.M.; Veraldi, S.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 152, No. 6, 2017, p. 642-650.

Research output: Contribution to journalArticle

Drago, L. ; Micali, G. ; Papini, M. ; Piraccini, B.M. ; Veraldi, S. / Management of mycoses in daily practice. In: Giornale Italiano di Dermatologia e Venereologia. 2017 ; Vol. 152, No. 6. pp. 642-650.
@article{ae1b607721384a019efa22baf1ab22db,
title = "Management of mycoses in daily practice",
abstract = "The guideline recommendations, albeit founded on thorough reviews of clinically relevant literature data, are often not immediately adaptable to everyday life. Considering the marked heterogeneity of superficial mycoses, each of them requires specific management in a real life context; in all cases diagnostic confirmation is required with microscopic and culture examination. In tinea capitis oral therapy is necessary (minimum six weeks) and should be continued until clinical and, above all, mycological healing. In cases of tinea corporis, cruris or pedis, it may be necessary to associate oral therapy to topical treatment. The main oral antifungals are fluconazole, itraconazole and terbinafine. Fluconazole has favorable pharmacokinetic and pharmacodynamic characteristics, and is effective in most superficial mycoses, for example in cases of diffuse or recurrent pityriasis versicolor in which oral therapy with an azole derivative is useful. Topical treatment, lasting 6-12 months, is indicated in onychomycosis that is confined to one nail. In frequent cases of onychomycosis involving multiple nails or recurrence, oral therapy is necessary. Pharmacological history is important, given the possible interactions of some systemic drugs. In chronic or recurrent relapsing vulvovaginitis, first-choice therapy is oral fluconazole with a therapeutic regimen that respects the mycotic biorhythm (200 mg on days 1, 4, 11, 26, and subsequently 200 mg/week for 3 months).",
keywords = "allylamine, amorolfine, antifungal agent, ciclopirox, fluconazole, griseofulvin, itraconazole, miconazole, nystatin, terbinafine, candidiasis, chemical binding, dermatophytosis, drug bioavailability, drug elimination, drug half life, fungicidal activity, human, maximum plasma concentration, mycosis, nonhuman, onychomycosis, Review, tinea capitis, tinea corporis, tinea cruris, tinea pedis, tinea versicolor, vulvovaginitis, yeast",
author = "L. Drago and G. Micali and M. Papini and B.M. Piraccini and S. Veraldi",
year = "2017",
doi = "10.23736/S0392-0488.17.05683-8",
language = "English",
volume = "152",
pages = "642--650",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Management of mycoses in daily practice

AU - Drago, L.

AU - Micali, G.

AU - Papini, M.

AU - Piraccini, B.M.

AU - Veraldi, S.

PY - 2017

Y1 - 2017

N2 - The guideline recommendations, albeit founded on thorough reviews of clinically relevant literature data, are often not immediately adaptable to everyday life. Considering the marked heterogeneity of superficial mycoses, each of them requires specific management in a real life context; in all cases diagnostic confirmation is required with microscopic and culture examination. In tinea capitis oral therapy is necessary (minimum six weeks) and should be continued until clinical and, above all, mycological healing. In cases of tinea corporis, cruris or pedis, it may be necessary to associate oral therapy to topical treatment. The main oral antifungals are fluconazole, itraconazole and terbinafine. Fluconazole has favorable pharmacokinetic and pharmacodynamic characteristics, and is effective in most superficial mycoses, for example in cases of diffuse or recurrent pityriasis versicolor in which oral therapy with an azole derivative is useful. Topical treatment, lasting 6-12 months, is indicated in onychomycosis that is confined to one nail. In frequent cases of onychomycosis involving multiple nails or recurrence, oral therapy is necessary. Pharmacological history is important, given the possible interactions of some systemic drugs. In chronic or recurrent relapsing vulvovaginitis, first-choice therapy is oral fluconazole with a therapeutic regimen that respects the mycotic biorhythm (200 mg on days 1, 4, 11, 26, and subsequently 200 mg/week for 3 months).

AB - The guideline recommendations, albeit founded on thorough reviews of clinically relevant literature data, are often not immediately adaptable to everyday life. Considering the marked heterogeneity of superficial mycoses, each of them requires specific management in a real life context; in all cases diagnostic confirmation is required with microscopic and culture examination. In tinea capitis oral therapy is necessary (minimum six weeks) and should be continued until clinical and, above all, mycological healing. In cases of tinea corporis, cruris or pedis, it may be necessary to associate oral therapy to topical treatment. The main oral antifungals are fluconazole, itraconazole and terbinafine. Fluconazole has favorable pharmacokinetic and pharmacodynamic characteristics, and is effective in most superficial mycoses, for example in cases of diffuse or recurrent pityriasis versicolor in which oral therapy with an azole derivative is useful. Topical treatment, lasting 6-12 months, is indicated in onychomycosis that is confined to one nail. In frequent cases of onychomycosis involving multiple nails or recurrence, oral therapy is necessary. Pharmacological history is important, given the possible interactions of some systemic drugs. In chronic or recurrent relapsing vulvovaginitis, first-choice therapy is oral fluconazole with a therapeutic regimen that respects the mycotic biorhythm (200 mg on days 1, 4, 11, 26, and subsequently 200 mg/week for 3 months).

KW - allylamine

KW - amorolfine

KW - antifungal agent

KW - ciclopirox

KW - fluconazole

KW - griseofulvin

KW - itraconazole

KW - miconazole

KW - nystatin

KW - terbinafine, candidiasis

KW - chemical binding

KW - dermatophytosis

KW - drug bioavailability

KW - drug elimination

KW - drug half life

KW - fungicidal activity

KW - human

KW - maximum plasma concentration

KW - mycosis

KW - nonhuman

KW - onychomycosis

KW - Review

KW - tinea capitis

KW - tinea corporis

KW - tinea cruris

KW - tinea pedis

KW - tinea versicolor

KW - vulvovaginitis

KW - yeast

U2 - 10.23736/S0392-0488.17.05683-8

DO - 10.23736/S0392-0488.17.05683-8

M3 - Article

VL - 152

SP - 642

EP - 650

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -